Results 1 to 10 of about 119,169 (307)
DNA-PKcs orchestrates CTLA-4 depletion-induced senescence in cancer cells [PDF]
Cell Death and DiseaseImmune checkpoints such as cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1) have been targeted in cancer therapy, however, the efficacy of these interventions remains limited.
Je-Jung Lee +7 more
doaj +2 more sources
CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis [PDF]
Scientific ReportsUveitis is a leading cause of blindness in the world and autoimmune uveitis is an ocular tissue specific autoimmune disease. Utilizing experimental autoimmune uveitis (EAU), we can interrogate different immune responses in the mouse that are relevant to ...
Minjun Ahn +3 more
doaj +2 more sources
A novel CTLA-4 deletion variant in a child with refractory autoimmune hemolytic anemia: molecular and functional characterization [PDF]
Frontiers in ImmunologyObjectiveAs a critical immune checkpoint, cytotoxic T-lymphocyte-associated protein 4(CTLA-4)deficiency is a well-established cause of inborn errors of immunity.
Feng Chen +7 more
doaj +2 more sources
A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice [PDF]
Nature CommunicationsCTLA-4 is a promising target for immune checkpoint inhibition in cancer therapy, with CTLA-4 blockade achieving prolonged overall survival for responding patients. However, the progressively elevated doses of anti-CTLA-4 agents, aimed at achieving better
Weian Cao +7 more
doaj +2 more sources
Frontiers in Medicine, 2021 Background: Rheumatoid arthritis (RA) is related to several pivotal susceptibility genes, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and costimulatory molecule (CD80/CD86) genes. Although the connection between polymorphisms of CTLA-4
Weixi Liu +7 more
doaj +1 more source
64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. [PDF]
PLoS ONE, 2014 Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) targeted therapy by anti-CTLA-4 monoclonal antibody (mAb) is highly effective in cancer patients.
Kei Higashikawa +6 more
doaj +1 more source
Identification of CTLA-4-Positive Cells in the Human Tonsil
Cells, 2021 CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) was originally defined as a T-lymphocyte antigen and was used as a target in cancer immunotherapy. Unfortunately, the existence of CTLA-4 in cells other than T-lymphocytes is often overlooked. The goal
Markus Tiemann +3 more
doaj +1 more source
mAbs, 2023 Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical inhibitory checkpoint molecule, and monoclonal antibodies (mAbs) targeting CTLA-4 that restore anti-tumor T cell immunity have achieved clinical success.
Jiawei Guan +16 more
doaj +1 more source
Molecules, 2023 Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a check point protein expressed on the surface of T cells and plays a central role in regulating the immune response.
Dong Wei +12 more
doaj +1 more source
Therapeutic options for CTLA-4 insufficiency
Journal of Allergy and Clinical Immunology, 2022 Heterozygous germline mutations in cytotoxic T lymphocyte-associated antigen-4 (CTLA4) impair the immunomodulatory function of regulatory T cells. Affected individuals are prone to life-threatening autoimmune and lymphoproliferative complications.
Egg, David +75 more
openaire +9 more sources